In a nutshell
- Bulgarian-led inHeart, closed $11M in funding, led by Vesalius Biocapital IV and co-led by Elaia Partners with participation from NACO, Sagana, Sofia Angel Ventures, CWR Funds, Cleverage VC, and Webit Investment Network.
- In addition, inHEART received funds from a successful crowd equity campaign on Tudigo and from the Astorg Foundation, Astorg Philanthropy Investments.
- The new funds will be utilized to drive commercial growth of their solution for cardiac ablation procedures, as well as to advance the development of the predictive cardiac models for heart failure, sudden cardiac death, and cardio-embolic stroke.
Their background story
inHEART, founded in 2017, is committed to delivering AI-enabled, a digital twin of the heart. The aim is to enhance the care of patients living with cardiac disease. The 3D models of the heart aim to allow physicians to optimize treatment strategies based on each patient’s unique cardiac anatomy. One of the company’s main objectives is to improve treatment strategies to support clinical outcomes.
Currently, inHEART is commercially available in the US and EU through a direct sales force model. The future plans include establishing a global distribution network.
Previously, the startup raised $200K from the Founders Games Grand Finals at the World Economic Forum (WEF) in Davos, hosted by Webit Foundation.
In their own words
“This new round allows us to go further in addressing the needs of cardiac patients from early screening and disease detection through advanced therapeutic support. It’s exciting for us to be at the forefront of transforming the healthcare industry with the power of AI technology by improving the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions,” said Todor Jeliaskov, Chairman and CEO of inHEART.
